BIO

Bio-Rad Laboratories Inc. (BIO) | Rumor.io

Bio-Rad Laboratories

BIO

Attention (50-day avg)0%

Attention rank (50-day avg)#2,159

Bullish sentiment (50-day avg)100%

Price to earnings ratio46.6

Market capitalization10.1B

Earnings per share8.19

Dividend yield (TTM)—

Revenue (annual)2.6B

Net income (annual)759.9M

Social

What share of all stock conversation is about BIO?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% +0	0% +0	0% 0

May 18

Activist investor Elliott Management has built a significant stake in Bio-Rad Laboratories ($BIO) after the stock fell over 70% from its 2021 peak.
Elliott's investment in Bio-Rad is primarily driven by the company's stake in Sartorius, a high-quality biologics and bioprocessing company, which is valued near $5 billion.
Elliott plans to pressure Bio-Rad to improve its underperforming stock through operational changes, aiming to boost the company's value and drive future growth.

Generated by AI

Sentiment

Of the messages about BIO that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	100%	92.1% +2.31
Bearish	—	—	0%	7.9% -2.31

Bullish· Oct 20

$BIO has shown a strong bounce off support and is ready for another move, with a potential setup for a clean entry in the lower Bollinger zone.
Bio-Rad Laboratories' recent BioXP revamp and VitaSTEM cooking are unlocking real utility and driving momentum for the company, with Asia being a key region for growth.
$BIO is maintaining its rebound from oversold levels, suggesting continued bullish momentum if buying persists, with potential for further gains as buyer interest strengthens.

Bearish· Aug 27

The asset's price is in a strong downtrend, with the price below multiple moving averages and the RSI hovering around the oversold region.
A break below the key support level could lead to fresh lows and further downside, with bearish momentum and limited bullish momentum.
The asset's float could be significantly reduced if it catches mainstream biotech attention, potentially leading to a rapid increase in price and a subsequent short squeeze.

Generated by AI

Topics

Of the messages about BIO that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Technical Analysis	100%	100%	100%	58.97%
Analysts	0%	0%	0%	0.21%
Announcements	0%	0%	0%	40.76%
Controversies	0%	0%	0%	0%
Earnings	0%	0%	0%	0.06%
Macro	0%	0%	0%	0%

Oct 10

Bio-Rad Laboratories, Inc. (BIO) is in talks to combine with fellow life-sciences company Qiagen in a deal worth more than $10 billion.
The combined company would be a major player in the life-sciences industry, with a market value of over $20 billion.
The deal is still in the negotiation phase, with no official announcement made by either company.

Generated by AI

Community

Of the messages about BIO, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	32.55%	32.4%	8.47%
Newcomers	100%	67.45%	67.6%	91.53%

Regulars· Aug 27

$BIO is in a strong downtrend, with the price below the 5, 10, and 20-hour moving averages, and the RSI is near the oversold region, indicating potential for a short-term bounce.
The formation of a descending triangle in $BIO suggests a potential bearish continuation, and the key support at $0.16 is crucial; if it breaks, fresh lows are likely before any bounce.
$BIO's current downtrend and technical indicators suggest limited bullish momentum, and a break below the support level could confirm further downside, with the next key level at $0.15.

Newcomers· May 18

Elliott has taken a significant stake in Bio-Rad Laboratories, potentially leading to improved performance from the company.
Bio-Rad's stake in Sartorius is valued at approximately $5 billion, making it a substantial asset for the company.
Elliott's investment in Bio-Rad may lead to increased pressure on the company to reallocate resources and improve margins.

Generated by AI

Bio-Rad Laboratories (NYSE:BIO) is pursuing a multi-year effort to improve growth, expand margins and strengthen free cash flow, with management emphasizing portfolio focus, operating discipline and a more selective approach to acquisitions. Speaking at a Bernstein conference, Chief Financial Offic

4d agoYahoo Finance

Bio-Rad at bernstein healthcare forum: shift toward profitable growth

5d agoInvesting.com

Biodesix Advances MRD Monitoring Programs With Bio-Rad and Thermo Fisher

Biodesix, Inc. (NASDAQ:BDSX) reported progress in two collaborative Molecular Residual Disease (MRD) monitoring programs designed to detect circulating tumor DNA (ctDNA) in blood following cancer treatment.

6d agoYahoo Finance

Biodesix advances MRD testing programs with Bio-Rad, Thermo Fisher

6d agoInvesting.com

Here's Why You Should Hold Bio-Rad Stock in Your Portfolio for Now

BIO's Clinical Diagnostics strength and international reach support growth, while China weakness, geopolitics and FX remain key risks.

6d agoYahoo Finance

Bio-Rad to Participate in Fireside Chat During Bernstein Insights Healthcare Leaders and Disruptors 3rd Annual Forum

HERCULES, Calif., September 16, 2026--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced that its Chief Financial Officer, Roop K. Lakkaraju, will participate in a fireside chat event during Bernstein Insights Healthcare Leaders and Disruptors 3rd Annual Forum on Thursday, September 24, 2026, at 8:50 AM Eastern Time.

13d agoYahoo Finance

Also Discussed

Investors talking about BIO also mention

#	Name	Attention
1	Bio ProtocolBIO	0%0
2	Encompass Health CorporationEHC	0%0
3	Henry Schein, Inc.HSIC	0%0
4	AMREP CorpAXR	0%0
5	Aka Brands Holding Corp.AKA	0%0
6	Allogene Therapeutics IncALLO	0%new
7	HUDSON PACIFIC PROPERTIES INCHPP	0%new
8	Envista Holdings Corp.NVST	0%0
9	BIOS - BioPlus Acquisition Corp.	——
10	Crane NXT, Co.CXT	0%0

Bio-Rad Laboratories Inc.

Healthcare
Medical Devices

Bio-Rad Laboratories Inc. is a life sciences and clinical diagnostics company that develops, manufactures, and markets products used in research laboratories, biopharmaceutical workflows, and healthcare testing. Bio-Rad Laboratories Inc. serves two main business segments: Life Science and Clinical Diagnostics. Its Life Science portfolio includes instruments, reagents, consumables, software, and content used to separate, purify, identify, and analyze biological materials such as cells, proteins, and nucleic acids. Its Clinical Diagnostics offerings include test systems, test kits, informatics tools, and quality controls used in areas such as diabetes monitoring, blood typing, infectious disease testing, autoimmune disorders, and genetic analysis. The company’s products are used by universities, hospitals, public health organizations, commercial laboratories, biotechnology firms, pharmaceutical companies, and food and environmental testing customers. Headquartered in Hercules, California, Bio-Rad Laboratories Inc. is recognized as a global supplier of tools that support scientific discovery and diagnostic decision-making.

Website

Location

1000 Alfred Nobel Drive

Hercules, CA, 94547

United States

Social

What share of all stock conversation is about BIO?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% +0	0% +0	0% 0

May 18

Activist investor Elliott Management has built a significant stake in Bio-Rad Laboratories ($BIO) after the stock fell over 70% from its 2021 peak.
Elliott's investment in Bio-Rad is primarily driven by the company's stake in Sartorius, a high-quality biologics and bioprocessing company, which is valued near $5 billion.
Elliott plans to pressure Bio-Rad to improve its underperforming stock through operational changes, aiming to boost the company's value and drive future growth.

Generated by AI

Sentiment

Of the messages about BIO that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	100%	92.1% +2.31
Bearish	—	—	0%	7.9% -2.31

Bullish· Oct 20

$BIO has shown a strong bounce off support and is ready for another move, with a potential setup for a clean entry in the lower Bollinger zone.
Bio-Rad Laboratories' recent BioXP revamp and VitaSTEM cooking are unlocking real utility and driving momentum for the company, with Asia being a key region for growth.
$BIO is maintaining its rebound from oversold levels, suggesting continued bullish momentum if buying persists, with potential for further gains as buyer interest strengthens.

Bearish· Aug 27

The asset's price is in a strong downtrend, with the price below multiple moving averages and the RSI hovering around the oversold region.
A break below the key support level could lead to fresh lows and further downside, with bearish momentum and limited bullish momentum.
The asset's float could be significantly reduced if it catches mainstream biotech attention, potentially leading to a rapid increase in price and a subsequent short squeeze.

Generated by AI

Topics

Of the messages about BIO that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Technical Analysis	100%	100%	100%	58.97%
Analysts	0%	0%	0%	0.21%
Announcements	0%	0%	0%	40.76%
Controversies	0%	0%	0%	0%
Earnings	0%	0%	0%	0.06%
Macro	0%	0%	0%	0%

Oct 10

Bio-Rad Laboratories, Inc. (BIO) is in talks to combine with fellow life-sciences company Qiagen in a deal worth more than $10 billion.
The combined company would be a major player in the life-sciences industry, with a market value of over $20 billion.
The deal is still in the negotiation phase, with no official announcement made by either company.

Generated by AI

Community

Of the messages about BIO, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	32.55%	32.4%	8.47%
Newcomers	100%	67.45%	67.6%	91.53%

Regulars· Aug 27

$BIO is in a strong downtrend, with the price below the 5, 10, and 20-hour moving averages, and the RSI is near the oversold region, indicating potential for a short-term bounce.
The formation of a descending triangle in $BIO suggests a potential bearish continuation, and the key support at $0.16 is crucial; if it breaks, fresh lows are likely before any bounce.
$BIO's current downtrend and technical indicators suggest limited bullish momentum, and a break below the support level could confirm further downside, with the next key level at $0.15.

Newcomers· May 18

Elliott has taken a significant stake in Bio-Rad Laboratories, potentially leading to improved performance from the company.
Bio-Rad's stake in Sartorius is valued at approximately $5 billion, making it a substantial asset for the company.
Elliott's investment in Bio-Rad may lead to increased pressure on the company to reallocate resources and improve margins.

Generated by AI

Bio-Rad Laboratories

Social

May 18

Sentiment

Bullish· Oct 20

Bearish· Aug 27

Topics

Oct 10

Community

Regulars· Aug 27

Newcomers· May 18

News

Bio-Rad Laboratories Bets on Digital PCR, Margins and Smarter M&A Growth

Bio-Rad at bernstein healthcare forum: shift toward profitable growth

Biodesix Advances MRD Monitoring Programs With Bio-Rad and Thermo Fisher

Biodesix advances MRD testing programs with Bio-Rad, Thermo Fisher

Here's Why You Should Hold Bio-Rad Stock in Your Portfolio for Now

Bio-Rad to Participate in Fireside Chat During Bernstein Insights Healthcare Leaders and Disruptors 3rd Annual Forum

Also Discussed

Bio-Rad Laboratories Inc.

Company Information

Location

News

Bio-Rad Laboratories Bets on Digital PCR, Margins and Smarter M&A Growth

Bio-Rad at bernstein healthcare forum: shift toward profitable growth

Biodesix Advances MRD Monitoring Programs With Bio-Rad and Thermo Fisher

Biodesix advances MRD testing programs with Bio-Rad, Thermo Fisher

Here's Why You Should Hold Bio-Rad Stock in Your Portfolio for Now

Bio-Rad to Participate in Fireside Chat During Bernstein Insights Healthcare Leaders and Disruptors 3rd Annual Forum

Also Discussed

Social

May 18

Sentiment

Bullish· Oct 20

Bearish· Aug 27

Topics

Oct 10

Community

Regulars· Aug 27

Newcomers· May 18